布地奈德混悬液联用复方异丙托溴铵吸入治疗96例婴幼儿哮喘的疗效评价

目的：评价用布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗婴幼儿哮喘的临床疗效。方法：采用随机分组方法,将2010年3月—2013年6月间萍乡市妇幼保健院儿科门诊内收治的确诊96例婴幼儿哮喘患者,分为观察组（48例）,给予布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗,对照组（48例）,给予常规方法治疗;将治疗前后的临床症状消失时间、临床疗效及不良反应情况等做一比较,并回顾性分析两组患儿的临床资料。结果：治疗后,观察组总有效率91.67%与对照组总有效率79.17%比较,其差异有统计学意义（P〈0.05）,观察组咳嗽,憋喘及肺部哮鸣音等临床症状的缓解或消失时间皆短于对照组（P〈0.05）,两组患儿均未发生不良反应。结论：用布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗婴幼儿哮喘,其疗效较显著,不良反应较少,安全性较高,值得临床使用。

Clinical Efficacy of Compound Ipratropium Combined with Budesonide Bromide Inhalation in Treatment of 96 Infants with Asthma

Objective： To analyze the clinical efficacy of compound ipratropium combined with budesonide bromide inhalation for asthma in infants. Methods： A randomized method was used in 96 cases of infants who were diagnosed with asthma in Pingxiang MCH Pediatric clinic during March 2010 to June 2013. They were divided into two groups in 48 cases observation group were treated with budesonide combined with ipratropium bromide inhalation therapy, in 48 cases the control group were treated with conventional methods. The clinical symptoms disappearing time af- tcr trcatmcnt clinical efficacy and adverse reactions were compared and analyzed retrospectively in the two groups. Re- sults： After treatment, the total effective rate was 91.67% in observation group, and it was 79.17% in the control group, thc diffcrcncc was statistically significant（P〈0.05）. The relieved or disappearina time of cough, hold breath and wheezing lungs and other clinical symptoms in observation group were shorter than that of the control group. The difference was statistically significant. Therc were no obvious adverse reactions in all children in the two groups. Conclusion： Compound ipratropium combined with budesonide bromide inhalation therapy for asthma in infants has fewer adverse reactions. It is safe and worthy of clinical use.